Assessed by IARC on November 18, 2019 during meeting 45 and on December 2, 2019 during meeting 46.

The committee considered IGHV1-69*01_S7220 (G163A) of submission S00010 of Genotype B16, which was previously evaluated as IGHV1-69*01_S5096 of submission S00006 at Meeting 10. It was affirmed as a Level 0 sequence at that time.

The sequence was seen in 8.02% of all unmutated rearrangements, with 53668 sequences including 22586 perfect matches to the inferred allele. There was abundant variation in the CDR3 regions of the aligned sequences. Three other alleles were present in the genotype, with IGHV1-69*02 also being present in the haplotype with this allele, likely a consequence of the presence of the IGHV1-69D gene in the haplotype in question. The inferred sequence includes six differences to the *02 allele. Haplotype data is supportive of the inference. There was strong support for the sequence being affirmed up to and including nucleotide 319, in line with IARC policy, as a Level 1 sequence, with one additional 3’ nucleotide being likely present in the sequence. This is indicated in IARC and OGRDB publications by one dot at the end of the sequence. It is noted that this sequences represents a 5’- and a 3’-extension of the partial allele IGHV1-69*07 already recognized by IMGT.